Article
Autoantibody origins in lupus and in relapse post CAR-T therapy
2025-10-20
Abstract excerpt
<h4>Summary</h4> Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that treatment-resistant disease is sustained by long-lived plasma cells. Additionally, emerging relapses highlight the need to understand how pathogenic autoantibodies arise. Using molecular antibody tagging in mice with human monogenic lupus variants,...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0f2fdd8f-f2c5-56fc-b29d-618e1e330018
- DOI
- 10.1101/2025.10.20.683393
